InsiderPulseNo transactions found.
| Date | Member | Chamber | Type | Amount |
|---|---|---|---|---|
| 2021-04-14 | Donald Sternoff Honorable Beyer(D-VA08) | house | Sale | $1,001 - $15,000 |
| 2020-11-20 | Donald Sternoff Beyer(D-VA08) | house | Purchase | $1,001 - $15,000 |
| 2020-07-14 | Donald Sternoff Beyer(D-VA08) | house | Sale | $1,001 - $15,000 |
| 2020-04-02 | Daniel Meuser(R-PA09) | house | Sale | $1,001 - $15,000 |
No financial data available for RHHBF.
Company may not file with SEC or CIK is unresolved.
Is Regeneron a Buy After the FDA Approved its Gene Therapy to Restore Hearing?
Alnylam Q1 Earnings Beat Estimates, Amvuttra Sales Drive Y/Y Growth
AI in Clinical Development Summit to Showcase Life Sciences and Technology Leaders Driving Real-World AI Impact
Roche to present extensive data showcasing its industry-leading ophthalmology portfolio at ARVO 2026
Genentech to Present Extensive Data Showcasing Its Industry-Leading Ophthalmology Portfolio at ARVO 2026
Microsoft says it has over 20M paid Copilot users, and they really are using it
Zealand Pharma and Roche to advance petrelintide, an amylin analog, to Phase 3 trials for chronic weight management
Regeneron Q1 Earnings Top, Sales Up on Dupixent & Eylea HD Strength
Regeneron Pharmaceuticals: Q1 Beat Driven By Dupixent And Eylea HD Strength
Roche: Policy Overhang Clears, Fundamentals Intact, Upside Remains Limited But Positive
Recursion Pharmaceuticals May Be Losing Ground To Its Peers
Merck: Bullish Setup Into Q1 Earnings